+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Analgesics Market By Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2020-2030

  • PDF Icon

    Report

  • 133 Pages
  • April 2022
  • Region: Global
  • Allied Market Research
  • ID: 5640604
The global analgesics market was valued at $26,654.4 million in 2020, and is projected to reach $50,682.6 million by 2030, registering a CAGR of 6.6% during the forecast period 2021-2030. Analgesics, also known as painkillers, are used to treat and reduce pain in the body. Typically, they are used when the pain is severe and becomes unbearable for the patient. Non-opioids, opioids, and compound analgesics (a combination of both, opioids and non-opioids) are the major analgesic products used globally. The emergence of painkillers is mainly attributed to the increase in acute and chronic diseases, as well as the rise in incidences of cancer globally.

Opioid drugs are the strongest types of painkillers, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.

The global analgesics market is expected to achieve moderate growth in the near future, majorly because of factors, such as increase in cardiovascular disease, cancer, and arthritis and surge in geriatric population. Recurring pain and aches experienced by the ageing population is another factor drives the market growth. In addition, increase in investments in R&D by public and private sectors, with key emphasis on the classes of compounds for formulating new therapeutics, is further expected to drive the analgesics market growth. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are expected to restrain the growth of the global analgesics market.

The analgesics market is segmented on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. By route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Region-wise, it is categorized into North America, Europe, Asia-Pacific, and LAMEA.

A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.

Key Benefits For Stakeholders

  • This report provides a detailed - Quantitative analysis of the current market trends and future estimations from 2021 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the analgesics market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments


By Type

  • Non opioids
  • Opioids

By Route of Administration

  • Rectal
  • Transdermal
  • Topical
  • Oral
  • Intravenous

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • Sweden
  • France
  • Russia
  • Denmark
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Indonesia
  • Rest of Asia-Pacific
  • LAMEA
  • Saudi Arabia
  • UAE
  • Morocco
  • Kenya
  • Nigeria
  • Brazil
  • Venezuela
  • Chile
  • Rest of LAMEA

Key Market Players

  • Abbott Laboratories
  • AbbVie Inc.
  • Bayer AG
  • Eli Lilly and Company
  • endo pharmaceuticals
  • Glaxosmithkline plc
  • johnson and johnson md&d
  • Pfizer, Inc.
  • Reckitt Benckiser Group
  • Sanofi

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: ANALGESICS MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Non opioids
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Opioids
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Intravenous
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Rectal
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Transdermal
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Topical
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: ANALGESICS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Type
6.2.3 North America Market size and forecast, by Route of Administration
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Type
6.2.4.1.2 Market size and forecast, by Route of Administration
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Type
6.2.4.2.2 Market size and forecast, by Route of Administration
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Type
6.2.4.3.2 Market size and forecast, by Route of Administration
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Type
6.3.3 Europe Market size and forecast, by Route of Administration
6.3.4 Europe Market size and forecast, by country
6.3.4.1 United Kingdom
6.3.4.1.1 Market size and forecast, by Type
6.3.4.1.2 Market size and forecast, by Route of Administration
6.3.4.2 Germany
6.3.4.2.1 Market size and forecast, by Type
6.3.4.2.2 Market size and forecast, by Route of Administration
6.3.4.3 Spain
6.3.4.3.1 Market size and forecast, by Type
6.3.4.3.2 Market size and forecast, by Route of Administration
6.3.4.4 Sweden
6.3.4.4.1 Market size and forecast, by Type
6.3.4.4.2 Market size and forecast, by Route of Administration
6.3.4.5 France
6.3.4.5.1 Market size and forecast, by Type
6.3.4.5.2 Market size and forecast, by Route of Administration
6.3.4.6 Russia
6.3.4.6.1 Market size and forecast, by Type
6.3.4.6.2 Market size and forecast, by Route of Administration
6.3.4.7 Denmark
6.3.4.7.1 Market size and forecast, by Type
6.3.4.7.2 Market size and forecast, by Route of Administration
6.3.4.8 Rest of Europe
6.3.4.8.1 Market size and forecast, by Type
6.3.4.8.2 Market size and forecast, by Route of Administration
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Type
6.4.3 Asia-Pacific Market size and forecast, by Route of Administration
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Type
6.4.4.1.2 Market size and forecast, by Route of Administration
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Type
6.4.4.2.2 Market size and forecast, by Route of Administration
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Type
6.4.4.3.2 Market size and forecast, by Route of Administration
6.4.4.4 Australia
6.4.4.4.1 Market size and forecast, by Type
6.4.4.4.2 Market size and forecast, by Route of Administration
6.4.4.5 Indonesia
6.4.4.5.1 Market size and forecast, by Type
6.4.4.5.2 Market size and forecast, by Route of Administration
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Type
6.4.4.6.2 Market size and forecast, by Route of Administration
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Type
6.5.3 LAMEA Market size and forecast, by Route of Administration
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Type
6.5.4.1.2 Market size and forecast, by Route of Administration
6.5.4.2 Venezuela
6.5.4.2.1 Market size and forecast, by Type
6.5.4.2.2 Market size and forecast, by Route of Administration
6.5.4.3 Chile
6.5.4.3.1 Market size and forecast, by Type
6.5.4.3.2 Market size and forecast, by Route of Administration
6.5.4.4 Saudi Arabia
6.5.4.4.1 Market size and forecast, by Type
6.5.4.4.2 Market size and forecast, by Route of Administration
6.5.4.5 UAE
6.5.4.5.1 Market size and forecast, by Type
6.5.4.5.2 Market size and forecast, by Route of Administration
6.5.4.6 Morocco
6.5.4.6.1 Market size and forecast, by Type
6.5.4.6.2 Market size and forecast, by Route of Administration
6.5.4.7 Kenya
6.5.4.7.1 Market size and forecast, by Type
6.5.4.7.2 Market size and forecast, by Route of Administration
6.5.4.8 Nigeria
6.5.4.8.1 Market size and forecast, by Type
6.5.4.8.2 Market size and forecast, by Route of Administration
6.5.4.9 Rest of LAMEA
6.5.4.9.1 Market size and forecast, by Type
6.5.4.9.2 Market size and forecast, by Route of Administration
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 AbbVie Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Bayer AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Eli Lilly and Company
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 endo pharmaceuticals
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Glaxosmithkline plc
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 johnson and johnson md&d
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Pfizer, Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Reckitt Benckiser Group
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Sanofi
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
LIST OF TABLES
Table 1. Global Analgesics Market, by Type, 2020-2030, ($Million)
Table 2. Analgesics Market Revenue, for Non Opioids, by Region, 2020-2030, ($Million)
Table 3. Analgesics Market Non Opioids by Country, 2020-2030, ($Million)
Table 4. Analgesics Market Revenue, for Opioids, by Region, 2020-2030, ($Million)
Table 5. Analgesics Market Opioids by Country, 2020-2030, ($Million)
Table 6. Global Analgesics Market, by Route of Administration, 2020-2030, ($Million)
Table 7. Analgesics Market Revenue, for Oral, by Region, 2020-2030, ($Million)
Table 8. Analgesics Market Oral by Country, 2020-2030, ($Million)
Table 9. Analgesics Market Revenue, for Intravenous, by Region, 2020-2030, ($Million)
Table 10. Analgesics Market Intravenous by Country, 2020-2030, ($Million)
Table 11. Analgesics Market Revenue, for Rectal, by Region, 2020-2030, ($Million)
Table 12. Analgesics Market Rectal by Country, 2020-2030, ($Million)
Table 13. Analgesics Market Revenue, for Transdermal, by Region, 2020-2030, ($Million)
Table 14. Analgesics Market Transdermal by Country, 2020-2030, ($Million)
Table 15. Analgesics Market Revenue, for Topical, by Region, 2020-2030, ($Million)
Table 16. Analgesics Market Topical by Country, 2020-2030, ($Million)
Table 17. Analgesics Market, by Region, 2020-2030, ($Million)
Table 18. North America Analgesics Market, by Type, 2020-2030, ($Million)
Table 19. North America Analgesics Market, by Route of Administration, 2020-2030, ($Million)
Table 20. North America Analgesics Market, by Country, 2020-2030, ($Million)
Table 21. U.S. Analgesics Market by Type 2020-2030, ($Million)
Table 22. U.S. Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 23. Canada Analgesics Market by Type 2020-2030, ($Million)
Table 24. Canada Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 25. Mexico Analgesics Market by Type 2020-2030, ($Million)
Table 26. Mexico Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 27. Europe Analgesics Market, by Type, 2020-2030, ($Million)
Table 28. Europe Analgesics Market, by Route of Administration, 2020-2030, ($Million)
Table 29. Europe Analgesics Market, by Country, 2020-2030, ($Million)
Table 30. United Kingdom Analgesics Market by Type 2020-2030, ($Million)
Table 31. United Kingdom Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 32. Germany Analgesics Market by Type 2020-2030, ($Million)
Table 33. Germany Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 34. Spain Analgesics Market by Type 2020-2030, ($Million)
Table 35. Spain Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 36. Sweden Analgesics Market by Type 2020-2030, ($Million)
Table 37. Sweden Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 38. France Analgesics Market by Type 2020-2030, ($Million)
Table 39. France Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 40. Russia Analgesics Market by Type 2020-2030, ($Million)
Table 41. Russia Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 42. Denmark Analgesics Market by Type 2020-2030, ($Million)
Table 43. Denmark Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 44. Rest of Europe Analgesics Market by Type 2020-2030, ($Million)
Table 45. Rest of Europe Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 46. Asia-Pacific Analgesics Market, by Type, 2020-2030, ($Million)
Table 47. Asia-Pacific Analgesics Market, by Route of Administration, 2020-2030, ($Million)
Table 48. Asia-Pacific Analgesics Market, by Country, 2020-2030, ($Million)
Table 49. Japan Analgesics Market by Type 2020-2030, ($Million)
Table 50. Japan Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 51. China Analgesics Market by Type 2020-2030, ($Million)
Table 52. China Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 53. India Analgesics Market by Type 2020-2030, ($Million)
Table 54. India Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 55. Australia Analgesics Market by Type 2020-2030, ($Million)
Table 56. Australia Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 57. Indonesia Analgesics Market by Type 2020-2030, ($Million)
Table 58. Indonesia Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 59. Rest of Asia-Pacific Analgesics Market by Type 2020-2030, ($Million)
Table 60. Rest of Asia-Pacific Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 61. LAMEA Analgesics Market, by Type, 2020-2030, ($Million)
Table 62. LAMEA Analgesics Market, by Route of Administration, 2020-2030, ($Million)
Table 63. LAMEA Analgesics Market, by Country, 2020-2030, ($Million)
Table 64. Brazil Analgesics Market by Type 2020-2030, ($Million)
Table 65. Brazil Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 66. Venezuela Analgesics Market by Type 2020-2030, ($Million)
Table 67. Venezuela Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 68. Chile Analgesics Market by Type 2020-2030, ($Million)
Table 69. Chile Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 70. Saudi Arabia Analgesics Market by Type 2020-2030, ($Million)
Table 71. Saudi Arabia Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 72. UAE Analgesics Market by Type 2020-2030, ($Million)
Table 73. UAE Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 74. Morocco Analgesics Market by Type 2020-2030, ($Million)
Table 75. Morocco Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 76. Kenya Analgesics Market by Type 2020-2030, ($Million)
Table 77. Kenya Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 78. Nigeria Analgesics Market by Type 2020-2030, ($Million)
Table 79. Nigeria Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 80. Rest of LAMEA Analgesics Market by Type 2020-2030, ($Million)
Table 81. Rest of LAMEA Analgesics Market by Route of Administration 2020-2030, ($Million)
Table 82. Abbott Laboratories: Company Snapshot
Table 83. Abbott Laboratories: Operating Segments
Table 84. Abbott Laboratories: Product Portfolio
Table 85. Abbott Laboratories: Net Sales
Table 86. Abbott Laboratories: Key Stratergies
Table 87. Abbvie Inc.: Company Snapshot
Table 88. Abbvie Inc.: Operating Segments
Table 89. Abbvie Inc.: Product Portfolio
Table 90. Abbvie Inc.: Net Sales
Table 91. Abbvie Inc.: Key Stratergies
Table 92. Bayer Ag: Company Snapshot
Table 93. Bayer Ag: Operating Segments
Table 94. Bayer Ag: Product Portfolio
Table 95. Bayer Ag: Net Sales
Table 96. Bayer Ag: Key Stratergies
Table 97. Eli Lilly and Company: Company Snapshot
Table 98. Eli Lilly and Company: Operating Segments
Table 99. Eli Lilly and Company: Product Portfolio
Table 100. Eli Lilly and Company: Net Sales
Table 101. Eli Lilly and Company: Key Stratergies
Table 102. Endo Pharmaceuticals: Company Snapshot
Table 103. Endo Pharmaceuticals: Operating Segments
Table 104. Endo Pharmaceuticals: Product Portfolio
Table 105. Endo Pharmaceuticals: Net Sales
Table 106. Endo Pharmaceuticals: Key Stratergies
Table 107. GlaxoSmithKline plc: Company Snapshot
Table 108. GlaxoSmithKline plc: Operating Segments
Table 109. GlaxoSmithKline plc: Product Portfolio
Table 110. GlaxoSmithKline plc: Net Sales
Table 111. GlaxoSmithKline plc: Key Stratergies
Table 112. Johnson and Johnson Md&D: Company Snapshot
Table 113. Johnson and Johnson Md&D: Operating Segments
Table 114. Johnson and Johnson Md&D: Product Portfolio
Table 115. Johnson and Johnson Md&D: Net Sales
Table 116. Johnson and Johnson Md&D: Key Stratergies
Table 117. Pfizer, Inc.: Company Snapshot
Table 118. Pfizer, Inc.: Operating Segments
Table 119. Pfizer, Inc.: Product Portfolio
Table 120. Pfizer, Inc.: Net Sales
Table 121. Pfizer, Inc.: Key Stratergies
Table 122. Reckitt Benckiser Group: Company Snapshot
Table 123. Reckitt Benckiser Group: Operating Segments
Table 124. Reckitt Benckiser Group: Product Portfolio
Table 125. Reckitt Benckiser Group: Net Sales
Table 126. Reckitt Benckiser Group: Key Stratergies
Table 127. Sanofi: Company Snapshot
Table 128. Sanofi: Operating Segments
Table 129. Sanofi: Product Portfolio
Table 130. Sanofi: Net Sales
Table 131. Sanofi: Key Stratergies
LIST OF FIGURES
Figure 1. Analgesics Market Segmentation
Figure 2. Analgesics Market, 2020-2030
Figure 3. Analgesics Market, 2020-2030
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Analgesics Market:Drivers, Restraints and Opportunities
Figure 12. Analgesics Market, by Type, 2020 (%)
Figure 13. Comparative Share Analysis of Non Opioids Analgesics Market, 2020-2030 (%)
Figure 14. Comparative Share Analysis of Opioids Analgesics Market, 2020-2030 (%)
Figure 15. Analgesics Market, by Route of Administration, 2020 (%)
Figure 16. Comparative Share Analysis of Oral Analgesics Market, 2020-2030 (%)
Figure 17. Comparative Share Analysis of Intravenous Analgesics Market, 2020-2030 (%)
Figure 18. Comparative Share Analysis of Rectal Analgesics Market, 2020-2030 (%)
Figure 19. Comparative Share Analysis of Transdermal Analgesics Market, 2020-2030 (%)
Figure 20. Comparative Share Analysis of Topical Analgesics Market, 2020-2030 (%)
Figure 21. Analgesics Market by Region, 2020
Figure 22. U.S. Analgesics Market, 2020-2030 ($Million)
Figure 23. Canada Analgesics Market, 2020-2030 ($Million)
Figure 24. Mexico Analgesics Market, 2020-2030 ($Million)
Figure 25. United Kingdom Analgesics Market, 2020-2030 ($Million)
Figure 26. Germany Analgesics Market, 2020-2030 ($Million)
Figure 27. Spain Analgesics Market, 2020-2030 ($Million)
Figure 28. Sweden Analgesics Market, 2020-2030 ($Million)
Figure 29. France Analgesics Market, 2020-2030 ($Million)
Figure 30. Russia Analgesics Market, 2020-2030 ($Million)
Figure 31. Denmark Analgesics Market, 2020-2030 ($Million)
Figure 32. Rest of Europe Analgesics Market, 2020-2030 ($Million)
Figure 33. Japan Analgesics Market, 2020-2030 ($Million)
Figure 34. China Analgesics Market, 2020-2030 ($Million)
Figure 35. India Analgesics Market, 2020-2030 ($Million)
Figure 36. Australia Analgesics Market, 2020-2030 ($Million)
Figure 37. Indonesia Analgesics Market, 2020-2030 ($Million)
Figure 38. Rest of Asia-Pacific Analgesics Market, 2020-2030 ($Million)
Figure 39. Brazil Analgesics Market, 2020-2030 ($Million)
Figure 40. Venezuela Analgesics Market, 2020-2030 ($Million)
Figure 41. Chile Analgesics Market, 2020-2030 ($Million)
Figure 42. Saudi Arabia Analgesics Market, 2020-2030 ($Million)
Figure 43. Uae Analgesics Market, 2020-2030 ($Million)
Figure 44. Morocco Analgesics Market, 2020-2030 ($Million)
Figure 45. Kenya Analgesics Market, 2020-2030 ($Million)
Figure 46. Nigeria Analgesics Market, 2020-2030 ($Million)
Figure 47. Rest of LAMEA Analgesics Market, 2020-2030 ($Million)
Figure 48. Top Winning Strategies, by Year
Figure 49. Top Winning Strategies, by Development
Figure 50. Top Winning Strategies, by Company
Figure 51. Product Mapping of Top 10 Players
Figure 52. Competitive Dashboard
Figure 53. Competitive Heatmap of Top 10 Key Players
Figure 54. Abbott Laboratories.: Net Sales, ($Million)
Figure 55. Abbvie Inc. Net Sales, ($Million)
Figure 56. Bayer AG.: Net Sales, ($Million)
Figure 57. Eli Lilly and Company.: Net Sales, ($Million)
Figure 58. Endo Pharmaceuticals.: Net Sales, ($Million)
Figure 59. GlaxoSmithKline PLC.: Net Sales, ($Million)
Figure 60. Johnson and Johnson Md&D.: Net Sales, ($Million)
Figure 61. Pfizer, Inc. Net Sales, ($Million)
Figure 62. Reckitt Benckiser Group.: Net Sales, ($Million)
Figure 63. Sanofi.: Net Sales, ($Million)

Executive Summary

According to this report titled, 'Analgesics Market,' The analgesics market size was valued at $26.7 billion in 2020, and is estimated to reach $50.7 billion by 2030, growing at a CAGR of 6.6% from 2021 to 2030. Currently, non-opioids occupy the major share of the market and are expected to continue to be the highest revenue-generating segment during the forecast period. The developed economies, namely North America and Europe, are likely to remain leading revenue-generating economies, and collectively accounted for over half of the overall market share in the global analgesics market in 2020.

In the current business scenario, there is increase in the incidences of chronic diseases, such as tuberculosis (TB), cancer, cardiovascular diseases, and arthritis, and rise in OTC analgesics market growth. In addition, there is a substantial rise in the number of patients due to infectious diseases, such as gastrointestinal, respiratory, and neurology. Increase in these diseases increases the demand for painkillers, which is expected to further drive the growth of the analgesics market. Moreeover, the increase in demand for over the counter (OTC) drug, is one of the factor responsible for the growth of OTC analgesics market.

The global analgesics market analysis is expected to attain substantial growth in the near future, owing to growing geriatric population coupled with increase in incidences of cardiovascular disease, cancer, and arthritis. Frequent pain and aches experienced by the ageing population are the other favorable factors that drive the market growth. In addition, rise in investments in R&D activities in analgesics industry, with key focus on the classes of compounds to formulate new therapeutics, is expected to drive the market growth during the analgesics market forecast period. However, factors such as uncontrolled prescriptions of opioids and drug abuse, leading to approximately 28,000 deaths in the U.S. every year, and insufficient regulatory guidelines, especially against opioid analgesics, are likely to impede the market growth. Thus, increase in popularity of personalized medicine, and surge in demand for analgesics industry is expected to provide numerous growth opportunities for the analgesics market in the near future.

The oral analgesics segment generated the highest revenue and is anticipated to maintain this trend during the forecast period. This is mainly attributed to the higher use of oral analgesics as compared to intravenous and topical analgesics. Economical cost, ease of availability, and high popularity of oral analgesics are the key factors responsible for the dominance of this segment.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global analgesics market share. The COVID-19 pandemic has stressed healthcare systems in the world and increased the need for advanced hospitals. Implementation of the spread of COVID-19 infection increased the demand for analgesic drug such as paracetamol, and drive the growth of the market.

Key Findings of Study
This report offers a detailed quantitative analysis of the current & future market trends from 2021 to 2030 to identify the prevailing opportunities.

The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.

The global analgesics market is comprehensively analyzed with respect to types and geography.

In-depth analysis based on geography facilitates to analyze the regional trends to assist in strategic business planning.

The developmental strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Bayer AG
  • Eli Lilly and Company
  • endo pharmaceuticals
  • Glaxosmithkline plc
  • johnson and johnson md&d
  • Pfizer, Inc.
  • Reckitt Benckiser Group
  • Sanofi

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information